<DOC>
	<DOC>NCT02069717</DOC>
	<brief_summary>The purpose of this study was to assess the incidence rate of the major adverse cardiovascular events (MACE) and safety of fenofibrate (Lipilfen capsule) add-on statin therapy in patients who have history of acute myocardial infarction and are diagnosed with metabolic syndrome.</brief_summary>
	<brief_title>Observational Study to Assess the Incidence Rate of the Major Adverse Cardiovascular Events (MACE) and Safety of Fenofibrate (Lipilfen Capsule)</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>patients &gt;20 years of age. history of acute myocardial infarction metabolic syndrome diagnosis current liver disease or AST or ALT greater than 3 times the upper limit of reference range preexisting gallbladder disease moderate to severe renal disorder (serum creatinine &gt;2.5mg/dL) pancreatitis diagnosis</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>